Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy

International Journal of Oncology

Volumn 34, Issue 6, 2009, Pages 1701-1715

  Bellone, Graziella ^a   Novarino, Anna ^b   Vizio, Barbara ^a   Brondino, Gabriele ^a   Addeo, Alfredo ^b   Prati, Adriana ^a   Giacobino, Alice ^b   Campra, Donata ^b   Fronda, Gian Ruggero ^b   Ciuffreda, Libero ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Chemotherapy; Immunotherapy; Pancreatic carcinoma; Surgery; Tumor immunity

Indexed keywords

CD3 ANTIBODY; CHROMIUM 51; CISPLATIN; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW CELL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CD95+ T LYMPHOCYTE; CELL STIMULATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOTHERAPY; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; LYMPHOKINE ACTIVATED KILLER CELL; MALE; METASTASIS; MIXED LYMPHOCYTE REACTION; NATURAL KILLER CELL; PALLIATIVE THERAPY; PANCREAS CARCINOMA; PANCREAS SURGERY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; T LYMPHOCYTE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD8-POSITIVE T-LYMPHOCYTES; CISPLATIN; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; DEOXYCYTIDINE; FEMALE; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-12 SUBUNIT P40; KILLER CELLS, LYMPHOKINE-ACTIVATED; LIPOPOLYSACCHARIDES; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; PILOT PROJECTS; PROGNOSIS; SURVIVAL RATE; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 67649422143     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000301     Document Type: Article

References (81)

1. Parkin DM, Bray FI and Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer 37: S4-S66, 2001.
2. Kuvshinoff BW and Bryer MP: Treatment of resectable and locally advanced pancreatic cancer. Cancer Control 7: 428-436, 2000.
3. Cohen SJ, Pinover WH, Watson JC and Meropol NJ: Pancreatic cancer. Curr Treat Options Oncol 1: 375-386, 2000.
4. Philip PA: Gemcitabine and platinum combinations in pancreatic cancer. Cancer 95: 908-911, 2002.
5. Oettle H and Riess H: Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer 95: 912-922, 2002.
6. Ducreux M, Boige V and Malka D: Treatment of advanced pancreatic cancer. Semin Oncol 34: S25-S30, 2007.
7. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117, 1991.
8. Nowak AK, Robinson BW and Lake RA: Gemcitabine exerts a selective effect on the humoral immune response:implications for combination chemo-immunotherapy. Cancer Res 62: 2353-2358, 2002.
9. Nio Y, Hirahara N, Minari Y, Iguchi C, Yamasawa K, Toga T and Tamura K: Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface. Anticancer Res 20: 3293-3299, 2000.
10. Merritt RE, Mahtabifard A, Yamada RE, Crystal RG and Korst RJ: Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer. J Thorac Cardiovasc Surg 126: 1609-1617, 2003.
11. Okamoto M, Ohe G, Oshikawa T, Nishikawa H, Furuichi S, Yoshida H and Sato M: Induction of cytokines and killer cell activities by cisplatin and 5-fluorouracil in head and neck cancer patients. Anticancer Drugs 11: 165-173, 2000.
12. Goldrosen MH, Dasmahapatra K, Jenkins D, Howell JH, Arbuck SG, Moore MC and Douglass HO Jr: Microplate leucocyte adherence inhibition (LAI) assay in pancreatic cancer: detection of specific antitumor immunity with patients' peripheral blood cells and serum. Cancer 47: 1614-1619, 1981.
13. Scupoli MT, Sartoris S, Tosi G, Ennas MG, Nicolis M, Cestari T, Zamboni G, Martignoni G, Lemoine NR, Scarpa A and Accolla RS: Expression of MHC class I and class II antigens in pancreatic adenocarcinomas. Tissue Antigens 48: 301-311, 1996.
14. Marincola FM, Jaffee EM, Hicklin DJ and Ferrone S: Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74: 181-273, 2000.
15. von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C, Henne-Bruns D, Kremer B and Kalthoff H: Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7: 925s-932s, 2001.
16. Igney FH and Krammer PH: Tumor counterattack: fact or fiction? Cancer Immunol Immunother 54: 1127-1136, 2005.
17. Bellone G, Smirne C, Carbone A, Mareschi K, Dughera L, Farina EC, Alabiso O, Valente G, Emanuelli G and Rodeck U: Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma. Clin Cancer Res 6: 2448-2455, 2000.
18. Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino A, Dughera L, Robecchi A, Pirisi M and Emanuelli G: Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 55: 684-698, 2006.
19. Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Ribecchi A, Emanuelli G and Rodeck U: Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 155: 537-547, 1999.
20. Bellone G, Carbone A, Smirne C, Scirelli T, Buffolino A, Novarino A, Stacchini A, Bertetto O, Palestro G, Sorio C, Scarpa A, Emanuelli G and Rodeck U: Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol 177: 3448-3460, 2006.
21. Kawakami Y, Okada T and Akada M: Development of immunotherapy for pancreatic cancer. Pancreas 28: 320-325, 2004.
22. Lake RA and Robinson BW: Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 5: 397-405, 2005.
23. Schultz ES and Schuler G: Malignant melanoma. Diagnosis and therapy. HNO 53: 928-939, 2005.
24. van der Most RG, Currie A, Robinson and Lake RA: Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res 66: 601-604, 2006.
25. Nowak AK, Lake RA and Robinson BW: Combined chemo-immunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev 58: 975-990, 2006.
26. Sobin LH and Wittekind CL: International Union Against Cancer (UICC). TNM classification of malignant tumors. John Wiley & Sons, Inc, New York, 2002.
27. Novarino A, Chiappino I, Bertelli GF, Heouaine A, Ritorto G, Addeo A, Bellone G, Merlano M and Bertetto O: Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer. Ann Oncol 15: 474-477, 2004.
28. Robinson SP, Patterson S, English N, Davies D, Knight SC and Reid CD: Human peripheral blood contains two distinct lineages of dendritic cells. Eur J Immunol 29: 2769-2778, 1999.
29. Shin JY, Lee SK, Kang CD, Chung JS, Lee EY, Seo SY, Lee SY, Baek SY, Kim BS, Kim JB and Yoon S: Antitumor effect of intratumoral administration of dendritic cell combination with vincristine chemotherapy in a murine fibrosarcoma model. Histol Histopathol 18: 435-447, 2003.
30. Yu B, Kusmartsev S, Cheng F, Paolini M, Nefedova Y, Sotomayor E and Gabrilovich D: Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res 9: 285-294, 2003.
31. Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bonmassar E and Francini G: Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 23: 8950-8958, 2005.
32. Ko HJ, Kim YJ, Kim YS Chang WS, Ko SY, Chang SY, Sakaguchi S and Kang CY: A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 67: 7477-7486, 2007.
33. + T lymphocytes. Clin Exp Immunol 150: 523-530, 2007.
34. Micheau O, Solary E, Hammann A, Martin F and Dimanche-Boitrel MT: Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst 89: 783-789, 1997.
35. Emens LA: Chemotherapy and tumor immunity: an unexpected collaboration. Front Biosci 13: 249-257, 2008.
36. Ménard C, Martin F, Apetoh L, Bouyer F and Ghiringhelli F: Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 57: 1579-1587, 2008.
37. Whiteside TL: Apoptosis of immune cells in the tumor microenvironment and peripheral circulation of patients with cancer: implications for immunotherapy. Vaccine 20: A46-A51, 2002.
38. Kusmartsev S and Gabrilovich DI: Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 25: 323-331, 2006.
39. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R and Liu YJ: Reciprocal control of T helper cell and dendritic cell differentiation. Science 283: 1183-1186, 1999.
40. Kuwana M: Induction of anergic and regulatory T cells by plasmacytoid dendritic cells and other dendritic cell subsets, Hum Immunol 63: 1156-1163, 2002.
41. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP and Gabrilovich DI: Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6: 1755-1766, 2000.
42. Della Bella S, Gennaro M, Vaccai M, Ferraris C, Nicola S, Riva A, Clerici M, Greco M and Villa ML: Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 89: 1463-1472, 2003.
43. Atzpodien J and Kirchner H: Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr 68: 1-11, 1990.
44. Kammula US and Marincola FM: Cancer immunotherapy: is there real progress at last? BioDrugs 11: 249-260, 1999.
45. Balch CM, Itoh K and Tilden AB: Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor. Surgery 98: 151-157, 1985.
46. Monson JR, Ramsden CW, Giles GR, Brennan TG and Guillou PJ: Lymphokine activated killer (LAK) cells in patients with gastrointestinal cancer. Gut 28: 1420-1425, 1987.
47. Baxevanis CN, Reclos GJ, Gritzapis AD, Dedousis GV, Missitzis I and Papamichail M: Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer 72: 491-501, 1993.
48. McCulloch PG and MacIntyre A: Effects of surgery on the generation of lymphokine-activated killer cells in patients with breast cancer. Br J Surg 80: 1005-1007, 1993.
49. Bauernhofer T, Kuss I, Henderson B, Baum AS and Whiteside TL: Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur J Immunol 33: 119-124, 2003.
50. Biassoni R, Cantoni C, Pende D, Sivori S, Parolini S, Vitale M, Bottino C and Moretta A: Human natural killer cell receptors and co-receptors. Immunol Rev 181: 203-214, 2001.
51. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F and Stern PL: Natural history of HLA expression during tumor development. Immunol Today 14: 491-493, 1993.
52. Hicklin DJ, Marincola FM and Ferrone S: HLA class I antigen downregulation in human cancers: T cell immunotherapy revives an old story. Mol Med Today 5: 178-186, 1999.
53. Garrido F, Ruiz-Cabello F, Cabrera T, Pérez-Villar JJ, López-Botet M, Duggan-Keen M and Stern PL: Implications for immunosurveillance of altered class I phenotypes in humans tumors. Immunol Today 18: 89-95, 1997.
54. Romagnani S: Human TH1 and TH2 subsets: doubt no more. Immunol Today 12: 256-257, 1991.
55. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL and Kurzrock R: Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 101: 2727-2736, 2004.
56. Trinchieri G: Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13: 251-276, 1995.
57. Hilkens CM, Kalinski P, de Boer M and Kapsenberg ML: Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 90: 1920-1926, 1997.
58. Germann T, Rüde E, Mattner F and Gately MK: The IL-12 p40 homodimer as a specific antagonist of the IL-12 heterodimer. Immunol Today 16: 500-501, 1995.
59. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146, 2003.
60. Kastelein RA, Hunter CA and Cua DJ: Discovery and biology of IL-23 and IL-27: Related but functionally distinct regulators of inflammation. Annu Rev Immunol 25: 221-242, 2007.
61. Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G, Shimamura H, Shibuya K, Takeda K and Matsuno S: Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 60: 1111-1116, 2000.
62. Shakhar G and Ben-Eliyahu S: Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 10: 972-992, 2003.
63. Takahashi K, Toyokawa H, Takai S, Satoi S, Yanagimoto H, Terakawa N, Araki H, Kwon AH and Kamiyama Y: Surgical influence of pancreatectomy on the function and count of circulating dendritic cells in patients with pancreatic cancer. Cancer Immunol Immunother 55: 775-784, 2006.
64. Abbruzzese JL: Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality. Semin Oncol 29: 2-8, 2002.
65. Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, Adsay V, Weaver D and Shields AF: Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 92: 569-577, 2001.
66. Heinemann V, Wilke H, Mergenthaler HG, Clemens M, König H, Illiger HJ, Arning M, Schalhorn A, Possinger K and Fink U: Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 11: 1399-1403, 2000.
67. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E and Lopez M: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94: 902-910, 2002.
68. + T cells have a major 'post-licensing' role in CTL mediated anti-tumor immunity. J Immunol 165: 6047-6055, 2000.
69. Plate JM, Plate AE, Shott S, Bograd S and Harris JE: Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 54: 915-925, 2005.
70. Boon T and van der Bruggen P: Human tumor antigens recognized by T lymphocytes. J Exp Med 183: 725-729, 1996.
71. Imai K, Matsuyama S, Miyake S, Suga K and Nakachi K: Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356: 1795-1799, 2000.
72. Yang S and Haluska FG: Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. J Immunol 172: 4599-4608, 2004.
73. Collins JL and Kao MS: The anticancer drug, cisplatin, increases the naturally occurring cell mediated lysis of tumor cells. Cancer Immunol Immunother 29: 17-22, 1989.
74. Yamaue H, Tanimura H, Noguchi K, Iwahashi M, Tsunoda T, Tani M, Tamai M, Hotta T, Mizobata S and Arii K: Cisplatin treatment renders tumor cells more susceptible to attack by lymphokine-activated killer cells. J Clin Lab Immunol 35: 165-170, 1991.
75. Mizutani Y, Bonavida B, Nio Y and Yoshida O: Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells. Cancer 71: 1313-1321, 1993.
76. Matsuzaki I, Suzuki H, Kitamura M, Minamiya Y, Kawai H and Ogawa J: Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells. Oncology 59: 336-343, 2000.
77. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Frelinger JA and Robinson BW: Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170: 4905-4913, 2003.
78. Huang GC, Liu SY, Lin MH, Kuo YY and Liu YC: The synergistic cytotoxicity of cisplatin and taxol in killing oral squamous cell carcinoma. Jpn J Clin Oncol 34: 499-504, 2004.
79. Chhipa RR and Bhat MK: Bystander killing of breast cancer MCF-7 cells by MDA-MB-231 cells exposed to 5-fluorouracil is mediated via Fas. J Cell Biochem 101: 68-79, 2007.
80. Correale P, Del Vecchio MT, La Placa M, Montagnani F, Di Genova G, Savellini GG, Terrosi C, Mannucci S, Giorgi G, Francini G and Cusi MG: Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. J Immunother 31: 132-147, 2008.
81. Yanagimoto H, Takai S, Satoi S, Toyokawa H, Takahashi K, Terakawa N, Kwon AH and Kamiyama Y: Impaired function of circulating dendritic cells in patients with pancreatic cancer. Clin Immunol 114: 52-60, 2005.